SCHEMBL14489228

SCHEMBL14489228

C=C1[C@H](O[Si](C)(C)C(C)(C)C)CC(=C/C=C2\CCC[C@@]3(C)C2CC[C@@H]3[C@@H](C)CC)C[C@H]1O[Si](C)(C)C(C)(C)C

nearest known ligand 0.55

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
VDR P11473 10/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14112577 1.00 VDR (0.54) VDR
SCHEMBL10820227 1.00 VDR (0.54) VDR
SCHEMBL9010570 0.95 VDR (0.51) VDR
SCHEMBL10125580 0.95 VDR (0.51) VDR
SCHEMBL9010583 0.93 VDR (0.57) VDR
SCHEMBL4151503 0.92 VDR (0.53) VDR
SCHEMBL14494431 0.92 VDR (0.53) VDR
SCHEMBL9010622 0.91 VDR (0.56) VDR
SCHEMBL14357531 0.91 VDR (0.56) VDR
SCHEMBL13790483 0.91 VDR (0.51) VDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9221753-B2 Process for the synthesis of vitamin D compounds and intermediates for the synthesis of the compounds CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2015-12-29 US disclosed
US-20070135394-A1 Process for the synthesis of vitamin d compounds and intermediates for the synthesis of the compounds CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2007-06-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070135394-A1 Process for the synthesis of vitamin d compounds and intermediates for the synthesis of the compounds CYP24A1, CYP2R1, VDR VDR 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.